Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 241

1.

Mechanisms of high-dose testosterone.

Thoma C.

Nat Rev Urol. 2019 Jul 11. doi: 10.1038/s41585-019-0216-0. [Epub ahead of print] No abstract available.

PMID:
31296946
2.

A deep dish of urology advances in Chicago for AUA2019.

Thoma C.

Nat Rev Urol. 2019 Jul;16(7):388. doi: 10.1038/s41585-019-0209-z. No abstract available.

PMID:
31189970
3.

Targeting DLL3 in neuroendocrine prostate cancer.

Thoma C.

Nat Rev Urol. 2019 Jun;16(6):330. doi: 10.1038/s41585-019-0190-6. No abstract available.

PMID:
31040438
4.

Inhibition of the Interleukin-36 Pathway for the Treatment of Generalized Pustular Psoriasis.

Bachelez H, Choon SE, Marrakchi S, Burden AD, Tsai TF, Morita A, Turki H, Hall DB, Shear M, Baum P, Padula SJ, Thoma C.

N Engl J Med. 2019 Mar 7;380(10):981-983. doi: 10.1056/NEJMc1811317. No abstract available.

PMID:
30855749
5.

Autologous adipose tissue injection promising for treatment of perianal fistulas in Crohn's disease.

Thoma C.

Nat Rev Gastroenterol Hepatol. 2019 Apr;16(4):198. doi: 10.1038/s41575-019-0130-1. No abstract available.

PMID:
30837700
6.

Substantial expansion of the human gut microbiota genome catalogue.

Thoma C.

Nat Rev Gastroenterol Hepatol. 2019 Apr;16(4):198. doi: 10.1038/s41575-019-0129-7. No abstract available.

PMID:
30837699
7.

Bile salt hydrolases involved in the effectiveness of FMT for Clostridium difficile infection.

Thoma C.

Nat Rev Gastroenterol Hepatol. 2019 Apr;16(4):198. doi: 10.1038/s41575-019-0128-8. No abstract available.

PMID:
30837698
8.

IL-22 assures gut homeostasis.

Thoma C.

Nat Rev Gastroenterol Hepatol. 2019 Apr;16(4):199. doi: 10.1038/s41575-019-0124-z. No abstract available.

PMID:
30816346
9.

The degree of hepatic steatosis associates with impaired cardiac and autonomic function.

Houghton D, Zalewski P, Hallsworth K, Cassidy S, Thoma C, Avery L, Slomko J, Hardy T, Burt AD, Tiniakos D, Hollingsworth KG, Taylor R, Day CP, Masson S, McPherson S, Anstee QM, Newton JL, Trenell MI.

J Hepatol. 2019 Jun;70(6):1203-1213. doi: 10.1016/j.jhep.2019.01.035. Epub 2019 Feb 13.

10.

ACLF monocyte dysfunction.

Thoma C.

Nat Rev Gastroenterol Hepatol. 2019 Mar;16(3):140-141. doi: 10.1038/s41575-019-0119-9. No abstract available.

PMID:
30723265
11.

Reduction of visceral adipose tissue mass requires IL-6 signalling.

Thoma C.

Nat Rev Gastroenterol Hepatol. 2019 Mar;16(3):140. doi: 10.1038/s41575-019-0114-1. No abstract available.

PMID:
30675026
12.

Panel of 10 serum metabolites shows promise in the non-invasive detection of advanced fibrosis.

Thoma C.

Nat Rev Gastroenterol Hepatol. 2019 Mar;16(3):140. doi: 10.1038/s41575-019-0113-2. No abstract available.

PMID:
30675025
13.

Modified FOLFIRINOX superior to gemcitabine in resected pancreatic ductal adenocarcinoma.

Thoma C.

Nat Rev Gastroenterol Hepatol. 2019 Mar;16(3):140. doi: 10.1038/s41575-019-0112-3. No abstract available.

PMID:
30675024
14.

Preventing brain damage in necrotizing enterocolitis.

Thoma C.

Nat Rev Gastroenterol Hepatol. 2019 Feb;16(2):75. doi: 10.1038/s41575-019-0107-0. No abstract available.

PMID:
30643226
15.

TH cells tune intestinal stem cell fate.

Thoma C.

Nat Rev Gastroenterol Hepatol. 2019 Jan;16(1):3. doi: 10.1038/s41575-018-0096-4. No abstract available.

PMID:
30523280
16.

Experimental Measurements of Ion Heating in Collisional Plasma Shocks and Interpenetrating Supersonic Plasma Flows.

Langendorf SJ, Yates KC, Hsu SC, Thoma C, Gilmore M.

Phys Rev Lett. 2018 Nov 2;121(18):185001. doi: 10.1103/PhysRevLett.121.185001.

PMID:
30444415
17.

Decoding hepatocyte ploidy.

Thoma C.

Nat Rev Gastroenterol Hepatol. 2018 Nov;15(11):656. doi: 10.1038/s41575-018-0076-8. No abstract available.

PMID:
30323318
18.

Epidermal growth factor receptor blockers for the treatment of ovarian cancer.

Morrison J, Thoma C, Goodall RJ, Lyons TJ, Gaitskell K, Wiggans AJ, Bryant A.

Cochrane Database Syst Rev. 2018 Oct 16;10:CD007927. doi: 10.1002/14651858.CD007927.pub4.

PMID:
30321910
19.

Personalized response prediction.

Thoma C.

Nat Rev Gastroenterol Hepatol. 2018 Nov;15(11):657. doi: 10.1038/s41575-018-0072-z. No abstract available.

PMID:
30279467
20.

Bacteriophage virome in IBD.

Thoma C.

Nat Rev Gastroenterol Hepatol. 2018 Sep;15(9):520. doi: 10.1038/s41575-018-0056-z. No abstract available.

PMID:
30076371
21.

Inherited pancreatic cancer risk.

Thoma C.

Nat Rev Gastroenterol Hepatol. 2018 Aug;15(8):454. doi: 10.1038/s41575-018-0048-z. No abstract available.

PMID:
30002476
22.

Balance of stresses guides metastasis.

Thoma C.

Nat Rev Gastroenterol Hepatol. 2018 Sep;15(9):520. doi: 10.1038/s41575-018-0047-0. No abstract available.

PMID:
29985452
23.

Signal of GV1001 efficacy.

Thoma C.

Nat Rev Urol. 2018 Aug;15(8):466-467. doi: 10.1038/s41585-018-0030-0. No abstract available.

PMID:
29795249
24.

Aptamer effective in vivo.

Thoma C.

Nat Rev Urol. 2018 Jul;15(7):396-397. doi: 10.1038/s41585-018-0027-8. No abstract available.

PMID:
29769643
25.

Controlling mutational chaos.

Thoma C.

Nat Rev Urol. 2018 Jun;15(6):335. doi: 10.1038/s41585-018-0021-1. No abstract available.

PMID:
29743669
26.

Kidney cancer: Antibody pincer movement challenges sunitinib as standard therapy.

Thoma C.

Nat Rev Urol. 2018 May;15(5):261. doi: 10.1038/nrurol.2018.47. Epub 2018 Apr 10. No abstract available.

PMID:
29632348
27.

Prostate cancer: Quality of life during chemohormonal therapy.

Thoma C.

Nat Rev Urol. 2018 May;15(5):263. doi: 10.1038/nrurol.2018.44. Epub 2018 Apr 5. No abstract available.

PMID:
29620061
28.

Kidney cancer: Combining targeted and immunotherapy.

Thoma C.

Nat Rev Urol. 2018 May;15(5):263. doi: 10.1038/nrurol.2018.43. Epub 2018 Apr 5. No abstract available.

PMID:
29620060
29.

Erectile dysfunction: Neurotrophins to recover erectile function.

Thoma C.

Nat Rev Urol. 2018 May;15(5):263. doi: 10.1038/nrurol.2018.45. Epub 2018 Apr 5. No abstract available.

PMID:
29620059
30.

Prostate cancer: Validating radiographic progression-free survival.

Thoma C.

Nat Rev Urol. 2018 May;15(5):263. doi: 10.1038/nrurol.2018.46. Epub 2018 Apr 5. No abstract available.

PMID:
29620058
31.

Bladder cancer: Neuroendocrine disease genomics.

Thoma C.

Nat Rev Urol. 2018 May;15(5):262. doi: 10.1038/nrurol.2018.42. Epub 2018 Apr 5. No abstract available.

PMID:
29620057
32.

Prostate cancer: Radiosensitized by STAT5 blockade.

Thoma C.

Nat Rev Urol. 2018 Apr;15(4):203. doi: 10.1038/nrurol.2018.37. Epub 2018 Mar 20. No abstract available.

PMID:
29557394
33.

[An effective treatment concept for patients with substance use disorders].

Adorjan K, Thoma C, Tchipeva E, Janjic K, Leidger A, Hoch E, Koller G, Falkai P, Pogarell O, Karch S.

MMW Fortschr Med. 2017 Oct;159(Suppl 6):1-5. doi: 10.1007/s15006-017-0079-3. Epub 2017 Oct 5. German.

PMID:
29557094
34.

Prostate cancer: Enhancing VTP.

Thoma C.

Nat Rev Urol. 2018 Apr;15(4):204. doi: 10.1038/nrurol.2018.32. Epub 2018 Mar 13. No abstract available.

PMID:
29532804
35.

Bladder cancer: Mechanisms of anti-PDL1 resistance.

Thoma C.

Nat Rev Urol. 2018 Apr;15(4):201. doi: 10.1038/nrurol.2018.28. Epub 2018 Mar 6. No abstract available.

PMID:
29508844
36.

Prostate cancer: AR-Vs not predictive in mCRPC.

Thoma C.

Nat Rev Urol. 2018 Apr;15(4):203. doi: 10.1038/nrurol.2018.24. Epub 2018 Feb 27. No abstract available.

PMID:
29485129
37.

Bladder cancer: Improving NMIBC risk stratification.

Thoma C.

Nat Rev Urol. 2018 Mar;15(3):138. doi: 10.1038/nrurol.2018.13. Epub 2018 Feb 6. No abstract available.

PMID:
29405205
38.

Prostate cancer: Developing CAR T cell therapy.

Thoma C.

Nat Rev Urol. 2018 Mar;15(3):138. doi: 10.1038/nrurol.2018.4. Epub 2018 Jan 23. No abstract available.

PMID:
29359739
39.

Prostate cancer: Pitfalls of liquid biopsy tests.

Thoma C.

Nat Rev Urol. 2018 Feb;15(2):69. doi: 10.1038/nrurol.2017.222. Epub 2018 Jan 3. No abstract available.

PMID:
29297893
40.

Bladder cancer: IMvigor211 trial outcomes reported.

Thoma C.

Nat Rev Urol. 2018 Mar;15(3):137. doi: 10.1038/nrurol.2017.225. Epub 2018 Jan 3. No abstract available.

PMID:
29297891
41.

Prostate cancer: Predicting risk of metastasis after prostatectomy.

Thoma C.

Nat Rev Urol. 2018 Mar;15(3):137. doi: 10.1038/nrurol.2017.228. Epub 2018 Jan 3. No abstract available.

PMID:
29297890
42.

Bladder cancer: Chemotherapy and checkpoint blockade.

Thoma C.

Nat Rev Urol. 2018 Feb;15(2):70. doi: 10.1038/nrurol.2017.224. Epub 2018 Jan 3. No abstract available.

PMID:
29297889
43.

Bladder cancer: Activity and safety of avelumab in JAVELIN.

Thoma C.

Nat Rev Urol. 2018 Mar;15(3):137. doi: 10.1038/nrurol.2017.227. Epub 2018 Jan 3. No abstract available.

PMID:
29297888
44.

Prostate cancer: Utility of ADT during early salvage radiotherapy.

Thoma C.

Nat Rev Urol. 2018 Mar;15(3):137. doi: 10.1038/nrurol.2017.226. Epub 2018 Jan 3. No abstract available.

PMID:
29297887
45.

Bladder cancer: Genomics of noninvasive disease.

Thoma C.

Nat Rev Urol. 2018 Jan;15(1):1. doi: 10.1038/nrurol.2017.207. Epub 2017 Dec 5. No abstract available.

PMID:
29205203
46.

Prostate cancer: H2A.Zac activates neo-enhancers.

Thoma C.

Nat Rev Urol. 2018 Jan;15(1):3. doi: 10.1038/nrurol.2017.202. Epub 2017 Nov 28. No abstract available.

PMID:
29182604
47.

Prostate cancer: Response prediction with HSD3B1.

Thoma C.

Nat Rev Urol. 2017 Dec;14(12):699. doi: 10.1038/nrurol.2017.192. Epub 2017 Nov 14. No abstract available.

PMID:
29133938
48.

Prostate cancer: Brachytherapy monotherapy is efficacious.

Thoma C.

Nat Rev Urol. 2017 Dec;14(12):700. doi: 10.1038/nrurol.2017.195. Epub 2017 Nov 8. No abstract available.

PMID:
29116259
49.

Prostate cancer: Treatment after ADT plus docetaxel.

Thoma C.

Nat Rev Urol. 2017 Dec;14(12):700. doi: 10.1038/nrurol.2017.196. Epub 2017 Nov 8. No abstract available.

PMID:
29116258
50.

Prostate cancer: No benefit of combining custirsen with cabazitaxel.

Thoma C.

Nat Rev Urol. 2017 Dec;14(12):700. doi: 10.1038/nrurol.2017.193. Epub 2017 Nov 8. No abstract available.

PMID:
29116255

Supplemental Content

Support Center